HYBRID EVENT: You can participate in person at Valencia, Spain or Virtually from your home or work.
COVID-19 Drug Development
COVID-19 drug development is a research process to discover a preventative and therapeutic prescription of drugs that would control the severity of coronavirus disease. From 2020 to 2021, various drug companies, biotechnology firms, university research groups, and health organizations were started developing over 600 potential therapies for corona virus disease with various stages of preclinical or clinical research, with 391 therapeutic candidates in clinical trials, as of January 2021.
Committee Members
A C Matin
Stanford University, United States
Luis Jesus Villarreal Gomez
Universidad Autonoma de Baja California, Mexico
Miroslav Radenkovic
University of Belgrade, Serbia
Andreia Freitas
INIAV and REQUIMTE, Portugal PDDS 2023 Speakers
Wayne Kaesemeyer
Augusta Hypertension PC, United States
Richard Z. Cheng
Cheng Integrative Health Center, United States
Mario souza y machorro
International College of Superior Education, Mexico
Gurpreet Singh
Freyr Lifesciences Limited, United Kingdom
Liberata Sportiello
University of Campania “L. Vanvitelli”, Italy
Franz Josef Meyer Almes
University of Applied Sciences, GermanySubmit your abstract Today
Title : Nanomaterial-mediated systemically-administered m-rna-based Gene therapy directed exclusively to cancer, resulting in eradication of implanted orthotopic tumors with no side effects
A C Matin, Stanford University, United States
Title : Mucoadhesive electrospun fibers in oral drug delivery
Luis Jesus Villarreal Gomez, Universidad Autonoma de Baja California, Mexico
Title : Qualitative and quantitative measures of drugs’ placenta permeability - a chromatographic and computational approach
Anna Weronika Sobańska, Medical University of Lodz, Poland
Title : The signification of the blood-brain barrier to the transfer of essential and toxic mineral elements
Bartolome Ribas Ozonas, Royal National Academy of Pharmacy, Spain
Title : New excipient to formulate poorly soluble APIs
Rajendran Arunagiri, Eastman, United States
Title : Multi-detection of pharmaceutical contamination in environment
Andreia Freitas, INIAV and REQUIMTE, Portugal
Title : HDAC inhibitors with non-hydroxamate warhead
Franz Josef Meyer Almes, University of Applied Sciences, Germany
Title : The role of non-antibiotic drugs on the development of antibiotic resistance
Mujde Eryilmaz, Ankara University, Turkey
Title : Digital health: Education in clinical pharmacy and implementation in practice
Aysu selcuk, Ankara University, Turkey
Title : Pharmacovigilance – Important, current trends, challenges and opportunities
Gurpreet Singh, Freyr Lifesciences Limited, United Kingdom